|
Socioeconomic status category
|
---|
| |
Lowest/least affluent
|
Intermediate
|
Highest/most affluent
|
Total
|
---|
N (%)
| |
49,868 (27.8%)
|
37,128 (20.7%)
|
92,147 (51.36%)
|
179,143
|
Year at diagnosis
| | | | | |
2000-2006
|
n
|
31,380
|
23,844
|
59,359
|
114,583
|
% within SES
|
62.9%
|
64.2%
|
64.4%
|
64.0%
|
2007-2010
|
n
|
18,488
|
13,284
|
32,788
|
64,560
|
% within SES
|
37.1%
|
35.8%
|
35.6%
|
36.0%
|
Race/ethnicity
| | | | | |
White
|
n
|
25,016
|
25,283
|
70,136
|
120,435
|
% within SES
|
50.2%
|
68.1%
|
76.1%
|
67.2%
|
Black
|
n
|
5,454
|
2,349
|
2,834
|
10,637
|
% within SES
|
10.9%
|
6.3%
|
3.1%
|
5.9%
|
Hispanic
|
n
|
14,848
|
5,756
|
7,776
|
28,380
|
% within SES
|
29.8%
|
15.5%
|
8.4%
|
15.8%
|
API
|
n
|
4,550
|
3,740
|
11,401
|
19,691
|
% within SES
|
9.1%
|
10.1%
|
12.4%
|
11.0%
|
Age (years) at diagnosis
| | | | | |
<35
|
n
|
1,347
|
713
|
1,628
|
3,688
|
% within SES
|
2.7%
|
1.9%
|
1.8%
|
2.1%
|
35-69
|
n
|
35,557
|
25,924
|
66,589
|
128,070
|
% within SES
|
71.3%
|
69.8%
|
72.3%
|
71.5%
|
70-79
|
n
|
8,414
|
6,708
|
15,388
|
30,510
|
% within SES
|
16.9%
|
18.1%
|
16.7%
|
17.0%
|
80-89
|
n
|
4,022
|
3,349
|
7,565
|
14,936
|
% within SES
|
8.1%
|
9.0%
|
8.2%
|
8.3%
|
90+
|
n
|
528
|
434
|
977
|
1,939
|
% within SES
|
1.1%
|
1.2%
|
1.1%
|
1.1%
|
AJCC stage
| | | | | |
Stage 1
|
n
|
21,814
|
18,066
|
47,655
|
87,535
|
% within SES
|
43.7%
|
48.7%
|
51.7%
|
48.9%
|
Stage 2
|
n
|
21,082
|
14,776
|
35,550
|
71,408
|
% within SES
|
42.3%
|
39.8%
|
38.6%
|
39.9%
|
Stage 3
|
n
|
6,972
|
4,286
|
8,942
|
20,200
|
% within SES
|
14.0%
|
11.5%
|
9.7%
|
11.3%
|
ER/PR/HER2 subtype
| | | | | |
ER+/PR+/HER2-
|
n
|
18,434
|
15,088
|
40,900
|
74,422
|
% within SES
|
52.6%
|
56.6%
|
59.8%
|
57.2%
|
ER+/PR+/HER2+
|
n
|
3,521
|
2,519
|
6,204
|
12,244
|
% within SES
|
10.0%
|
9.5%
|
9.1%
|
9.4%
|
ER+/PR-/HER2-
|
n
|
3,264
|
2,548
|
6,702
|
12,514
|
% within SES
|
9.3%
|
9.6%
|
9.8%
|
9.6%
|
ER+/PR-/HER2+
|
n
|
1,180
|
856
|
2,082
|
4,118
|
% within SES
|
3.4%
|
3.2%
|
3.0%
|
3.2%
|
ER-/PR+/HER2-
|
n
|
285
|
212
|
527
|
1,024
|
% within SES
|
0.8%
|
0.8%
|
0.8%
|
0.8%
|
ER-/PR+/HER2+
|
n
|
167
|
120
|
226
|
513
|
% within SES
|
0.5%
|
0.5%
|
0.3%
|
0.4%
|
ER-/PR-/HER2-
|
n
|
5,454
|
3,550
|
7,821
|
16,825
|
% within SES
|
15.6%
|
13.3%
|
11.4%
|
100.0%
|
ER-/PR-/HER2+
|
n
|
2,744
|
1,753
|
3,941
|
12.9%
|
|
% within SES
|
7.8%
|
6.6%
|
5.8%
|
8,438
|
Tumor grade
|
n
|
9,276
|
7,998
|
22,058
|
39,332
|
Grade I
|
% within SES
|
19.9%
|
22.9%
|
25.3%
|
23.3%
|
n
|
18,814
|
14,625
|
37,837
|
71,276
|
Grade II
|
% within SES
|
40.3%
|
41.9%
|
43.4%
|
42.3%
|
n
|
17,586
|
11,572
|
25,888
|
55,046
|
Grade III
|
% within SES
|
37.7%
|
33.2%
|
29.7%
|
32.6%
|
n
|
1,001
|
698
|
1,344
|
3,043
|
Grade IV
|
% within SES
|
2.1%
|
2.0%
|
1.5%
|
1.8%
|
- *Excludes cases classified as American Indian and Hispanic + Other race.